(Q46598937)

English

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

scientific article published on 22 May 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/3674331

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis (English)

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/3674331

pharmacokinetics

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

author name string

H Tan

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

P Gupta

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

J Harness

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

R Wolk

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

S Chapel

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

A Menter

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

B Strober

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

RG Langley

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

S Krishnaswami

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

publication date

22 May 2013

1 reference

Europe PubMed Central

PMC publication ID

23 December 2017

http://europepmc.org/abstract/PMC/3674331

CPT: pharmacometrics & systems pharmacology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

e44-

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC3674331&resulttype=core&format=json

14 May 2020

Obesity and psoriasis: body weight and body mass index influence the response to biological treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

The BUGS project: Evolution, critique and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

Adipocytokines: mediators linking adipose tissue, inflammation and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

How modeling and simulation have enhanced decision making in new drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

24 May 2018

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

15 August 2018

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

15 August 2018

A case study of model-based Bayesian dose response estimation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

15 August 2018

Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674331

15 August 2018

Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy

1 reference

https://api.crossref.org/works/10.1038%2FPSP.2013.22

21 January 2018

Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FPSP.2013.22

31 March 2020

Adipose Tissue in the Regulation of Inflammation

1 reference

https://api.crossref.org/works/10.1038%2FPSP.2013.22

31 March 2020

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

1 reference

https://api.crossref.org/works/10.1038%2FPSP.2013.22

31 March 2020

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FPSP.2013.22

31 March 2020

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

https://api.crossref.org/works/10.1038%2FPSP.2013.22

31 March 2020

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

1 reference

https://api.crossref.org/works/10.1038%2FPSP.2013.22

31 March 2020

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1038%2FPSP.2013.22

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46598937&oldid=2144688076"